Tag: Chemotherapy

By Posted on Posted in Genetic Predisposition, Genetic Susceptibility, Personalized Hygiene, Pharmacogenetics, Thasso Post, Theragenomic Medicine, Theragenomics, Theragenomics of Individualized Drug Safety Tagged with , , , , , , , , , ,

June 23, 2022 – Expansion of pharmacogenetics education agreed as part of lawsuit settlement. This has just been the headline objective of one of the latest blogs from the PharmGKB blogspot, an NIH-funded resource (database) that provides information about how …

Real world theragenomics and personalised medicine Read more »

By Posted on Posted in New Drug Approval, Thasso Post Tagged with , , , , , ,

October 12, 2014 – The U.S. Food and Drug Administration, on October 10,  approved Akynzeo (netupitant and palonosetron) to treat nausea and vomiting in patients undergoing cancer chemotherapy. Akynzeo is a fixed combination capsule comprised of two drugs. Oral palonosetron approved …

Netupitant/Palonosetron [Akynzeo] for nausea and vomiting associated with cancer chemotherapy approved in the US Read more »